Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2022 07:30 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments

– Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD) at Angiogenesis, Exudation, and...
May 04, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan

- Betta Pharmaceuticals to develop and commercialize EYP-1901 in China, Hong Kong, Macau and Taiwan; EyePoint retains all global ophthalmic rights for EYP-1901 elsewhere - - Partnership strengthens...
April 27, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
April 21, 2022 16:31 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference

WATERTOWN, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
April 18, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
March 16, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
March 09, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank

WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
March 07, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer

WATERTOWN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
March 03, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments

– Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudation, and Degeneration 2022 virtual meeting on February 12, 2022, continuing positive safety and efficacy profile...
March 01, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference

WATERTOWN, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...